We recently published a list of Why These 15 Healthcare Stocks Are Surging in 2025. In this article, we are going to take a look at where Nuvectis Pharma Inc (NASDAQ:NVCT) stands against other healthcare stocks that are surging in 2025.
After lagging behind the broader market in 2024, many healthcare stocks are making a comeback this year. Healthcare spending has been continuously soaring and is projected to do so in the coming years due to demographic tailwinds. The industry now accounts for a fifth of the U.S. economy, and it’s a good idea to have exposure to it.
Most executives now hold a favorable view of the industry’s prospects, a notable increase from 52% just a year ago. Moreover, it’s an industry that is more insulated from tariffs and macro risks.
Of course, the top gainers here are not defensive healthcare stocks, but it’s still worth looking into the winners here if you are chasing potential multibaggers.
Even during bear markets, there are pockets of the market that perform exceptionally well. For example, I identified 15 Energy Stocks that are Up the Most in 2025 in another article.
Methodology
For this article, I screened the best-performing healthcare stocks year-to-date.
I will also mention the number of hedge fund investors in these stocks. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
A hand holding a vial containing a clear liquid, symbolizing the precision medicines developed by the company.
Nuvectis Pharma, Inc. (NASDAQ:NVCT)
Number of Hedge Fund Holders In Q4 2024: 5
Nuvectis Pharma, Inc. (NASDAQ:NVCT) is a clinical-stage biopharmaceutical company developing precision medicines for oncology, with lead candidates NXP800 for ARID1a-mutated ovarian cancer and NXP900, a first-in-class SRC/YES1 kinase inhibitor for solid tumors.
The main catalyst behind the stock’s sharp rise in 2025 has been investor enthusiasm around upcoming and ongoing presentations of NXP900 at the 2025 American Association for Cancer Research Meeting, scheduled for late April. Shares soared 5.28% on April 24, 2025, capping a three-day run with a cumulative gain of 31.41%, as anticipation built for the conference presentations detailing first-in-human clinical data for NXP900 in advanced solid tumors and its potential to overcome resistance in non-small cell lung cancer.
Earlier in the year, Nuvectis completed a $15.5 million public offering in February to fund continued development of NXP800 and NXP900, which further strengthened its balance sheet and positioned the company for key 2025 milestones.
The consensus price target of $15.67 implies 49.35% upside.
Nuvectis Pharma, Inc. (NASDAQ:NVCT) stock is up 93.90% year-to-date.
Overall, NVCT ranks 14th on our list of healthcare stocks that are surging in 2025. While we acknowledge the potential of NVCT as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than NVCT but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.
